β-Catenin signaling in hepatocellular carcinoma

Chuanrui Xu,1 Zhong Xu,2 Yi Zhang,3 Matthias Evert,4 Diego F. Calvisi,4 and Xin Chen5

1School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China. 3Key Laboratory of Bioreheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China. 4Institute of Pathology, University of Regensburg, Regensburg, Germany. 5Department of Bioengineering and Therapeutic Sciences and Liver Center, UCSF, San Francisco, California, USA.

Deregulated Wnt/β-catenin signaling is one of the main genetic alterations in human hepatocellular carcinoma (HCC). Comprehensive genomic analyses have revealed that gain-of-function mutation of CTNNB1, which encodes β-catenin, and loss-of-function mutation of AXIN1 occur in approximately 35% of human HCC samples. Human HCCs with activation of the Wnt/β-catenin pathway demonstrate unique gene expression patterns and pathological features. Activated Wnt/β-catenin synergizes with multiple signaling cascades to drive HCC formation, and it functions through its downstream effectors. Therefore, strategies targeting Wnt/β-catenin have been pursued as possible therapeutics against HCC. Here, we review the genetic alterations and oncogenic roles of aberrant Wnt/β-catenin signaling during hepatocarcinogenesis. In addition, we discuss the implication of this pathway in HCC diagnosis, classification, and personalized treatment.

Introduction

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, representing the third leading cause of cancer-related death (1). The incidence of HCC ranks sixth among all tumor types worldwide. Increased HCC occurrence in this decade reflects persistent hepatitis B and C virus infection and the increase of nonalcoholic steatohepatitis (NASH) since 2000 (2). A projection study indicated that the age-standardized incidence rates per 100,000 person-years for primary liver cancer would increase in both men and women by the year 2030 in most countries as a result of increased NAFLD and/or NASH (3). During the past decade, multitargeted tyrosine kinase inhibitors (TKIs), such as sorafenib, lenvatinib,regorafenib, and cabozantinib, have been used as first- or second-line drugs for patients with unresectable HCC (4). However, these agents provide limited survival benefits and are associated with considerable toxicities and poor quality-of-life outcomes. Immune checkpoint inhibitors (ICIs) have been approved for HCC treatment and show a similar response rate (15%-30%) compared with TKI therapies (5). For example, HCC patients who received the CTLA4-blocking ICI tremelimumab showed a partial response rate of 18% and a disease control rate of 76% (6). PD-1 and PD-L1 blockade showed higher objective response rates, which could reach 20% in advanced HCC patients (7). Recently, the phase III IMbrave150 trial results showed that combining an anti-PD-L1 antibody with an anti-VEGF-A antibody leads to promising efficacy for advanced HCC patients (8). Currently, this combination immunotherapy has become the first-line treatment strategy against HCC (9). Nevertheless, most patients eventually progress under this regimen. Therefore, studies to elucidate the molecular mechanisms underlying HCC pathogenesis are imperative to develop additional and more effective drugs for precision medicine.

Molecular mechanisms of Wnt/β-catenin activation in HCC

The Wnt/β-catenin cascade is one of the major signaling pathways regulating liver homeostasis, regeneration, and tumorigenesis (10), which has been extensively reviewed (11, 12). In brief, in the absence of Wnt ligands, most cellular β-catenin is sequestered in the adherens junctions at the plasma membrane (Figure 1). Cytosolic β-catenin associates in a complex with adenomatous polyposis coli (APC) and AXIN1 proteins, which mediate the N-terminal phosphorylation of β-catenin. This event leads to the ubiquitination of β-catenin by the E3 ubiquitin ligase β-transducin repeat-containing protein (β-TRCP) and subsequent proteasomal degradation. When Wnt ligands bind to the Frizzled receptors, Dvl/Dsh is phosphorylated and, in turn, recruits AXIN1 and GSK3β adjacent to the plasma membrane, thus preventing the formation of the degradation complex. As a result, unphosphorylated β-catenin escapes recognition by β-TRCP and translocates into the nucleus, where it binds to the T cell factor (TCF) and lymphoid enhancer-binding protein family (LEF) transcription factors. The activated β-catenin/TCF/LEF complex induces the transcription of genes regulating cell proliferation and survival (Figure 1).

In the normal liver, β-catenin is membrane-localized in hepatocytes, and the Wnt/β-catenin pathway is activated in pericentral hepatocytes, which is demonstrated by β-catenin–dependent glutamine synthetase (GS) staining in these cells (13, 14). In HCC, recent genomic studies revealed that 30% to 40% of tumors demonstrate aberrant activation of the Wnt/β-catenin cascade (15). The activation of this pathway could be subdivided into somatic genetic events and nongenetic events. For somatic mutations leading to Wnt/β-catenin activations, The Cancer Genome Atlas (TCGA) analysis reveals that gain-of-function (GOF) mutations of CTNNB1, which encodes β-catenin, occur in 27% of HCC patients (Figure 1). Most CTNNB1 missense mutations arise at the serine/threonine sites of exon 3 or adjacent amino acids, which prevents the β-catenin protein from phosphorylation and degradation, leading to its stabilization and unrestrained transcriptional
Unique features of HCC with Wnt/β-catenin activation

Studies have illustrated that human HCCs with aberrant Wnt/β-catenin activation have distinct clinical, pathological, and molecular features. Multiple investigations suggest that overexpression and mutations of β-catenin occur more frequently in HCV-related HCCs than in HBV-related HCCs (22–24) and are commonly observed in HCC with noncirrhotic liver in the absence of usual HCC risk factors (25, 26). Activation of the Wnt/β-catenin cascade has been linked to early-stage HCC (24, 27), but also tumor progression (28). Association between β-catenin activation and HCC patient survival remains controversial, with most studies suggesting that CTNNB1 mutation is a favorable prognostic marker. For instance, using meta-analysis, Wang et al. reported that HCC patients with CTNNB1 mutations demonstrate a more prolonged overall survival (29). Similar results came from a study by Ding et al. (30). However, Lu and colleagues reported that CTNNB1 mutations are not associated with prognosis in advanced HCC (31).

Studies have also revealed multiple nongenetic mechanisms leading to Wnt/β-catenin activation. These include promoter hypermethylation and related silencing of the secreted Frizzled-related protein 1 gene (SFRP1), a Wnt/β-catenin antagonist (18); overexpression of Frizzled (FZD) membrane receptor and Wnt ligands (19); and deregulated expression of microRNAs (20) and long noncoding RNAs (21) that regulate Wnt/β-catenin signaling.

Figure 1. Canonical Wnt/β-catenin signaling pathway in HCC. (A) When Wnt ligands are present, Wnt/FZD signaling activation leads to the phosphorylation of mammalian homolog of dishevelled (DVL). Phosphorylated DVL recruits AXIN and GSK3β to the plasma membrane, hence blocking the degradation complex’s formation. Subsequently, β-catenin accumulates in the cytoplasm and then translocates into the nucleus. Nuclear β-catenin binds to TCF/LEF transcription factors and promotes the transcription of target genes. (B) When Wnt ligands are absent, soluble β-catenin is phosphorylated by the GSK3β-CK1α-APC-AXIN1 complex. Once phosphorylated, β-catenin is degraded by the proteasome after ubiquitination by the Skp-, Culin-, and F-box-containing (SCF) protein complex. When β-catenin is absent in the nucleus, the TCF/LEF transcription factors are repressed by TLE-1. CTNNB1 (encoding β-catenin), AXIN1, and APC are mutated in 27%, 8%, and 3% of human HCCs, respectively.
overexpression have poorer cellular differentiation (32). In contrast, there were no significant differences in HCC tumor grade between β-catenin-positive and -negative tumors in two other investigations (33, 34). These discrepancies remain to be addressed and might be due to the different analyses conducted (using either HCCs with β-catenin mutations or nuclear accumulation of the protein for the comparisons) or the lack of a standard and specific delineation of β-catenin-“positive” tumors based on the staining patterns (i.e., the percentage of cells positive for nuclear β-catenin defining an HCC as either β-catenin positive or negative). Finally, Audard et al. were the first to try to outline macroscopic and microscopic features of CTNNB1-mutated HCCs (25). They demonstrated that CTNNB1-mutated HCCs are usually large (>6 cm in diameter) and solitary lesions. Typical, albeit non-pathognomonic, microscopic features of CTNNB1-mutated HCCs are microtrabecular and acinar growth, a high degree of differentiation (Edmondson grade G1–G2), homogeneous microscopic appearance, prominent cholestasis, and lack of steatosis and inflammation. Interestingly, they showed that robust and uniform immunohistochemical expression of glutamine synthetase (GS), a target of the Wnt/β-catenin pathway, was more sensitive (90%) than cytoplasmic/nuclear β-catenin positivity (63%) in identifying CTNNB1-mutated HCCs, though with equal specificity (both 98%). Indeed, based on TCGA analysis, the upregulation of GLUL, which encodes GS, and other canonical Wnt/β-catenin target genes is strongly associated with CTNNB1 mutation status in HCC (Figure 1). These results were confirmed by Calderaro et al. in a large study comparing the correlation of morphology and molecular features in a large cohort of HCCs (35).

Overall, human HCCs can be subdivided into two major groups: a proliferation group and a nonproliferation group (36, 37). Each of these groups accounts for approximately 50% of human HCCs and consists of several subgroups identified in various genomic studies (Figure 1B). In addition, based on TCGA studies, HCC could be classified into clusters 1, 2, and 3 (38). Clusters 1 and 3 belong to the proliferation group and cluster 2 to the nonproliferation group. Boyault et al. further defined human HCCs into G1 to G6 subgroups (39). Among them, G1, G2, and G3 are classified as proliferation group, whereas G4, G5, and G6 are defined as nonproliferation group. The proliferation group and the nonproliferation group show different molecular, genetic, epigenetic, and clinical features. The proliferation group is associated with chromosomal instability, DNA hypomethylation, alcohol- or HCV-related HCC, low serum α-fetoprotein levels, and low frequency of vascular invasion. In contrast, the nonproliferation group is characterized by chromosomal stability, promoter hypermethylation, frequent HBV infection, more aggressive phenotype, poor tumor differentiation, high serum α-fetoprotein levels, and increased vascular invasion (40). Intriguingly, GOF CTNNB1 mutations are frequently found in the nonproliferation group, and are associated with cluster 2 and G5/G6 subgroups (Figure 1B). In contrast, HCCs with AXIN1 mutations belong to the proliferation group, and are associated with cluster 1 and G1 subgroups (Figure 1B).

Induction of hepatocarcinogenesis by Wnt/β-catenin
Activated Wnt/β-catenin signaling has been considered an early signaling event in HCC pathogenesis (41, 42). Importantly, studies have shown that CTNNB1 mutation is one of the significant key genetic events in human HCCs (43, 44). Furthermore, Wnt/β-catenin has also been implicated in HCC stemness, progression, metastasis, and drug resistance (45–49). For instance, this pathway has been identified as the prominent signaling that causes the proliferation of cancer stem cells (CSCs). Indeed, overexpression of β-catenin increases self-renewal and in vivo tumorigenicity of HCC CSCs (50–52). Furthermore, activated Wnt/β-catenin has also been associated with resistance to sorafenib and regorafenib in HCC patients (51, 53). All these data support the critical roles of Wnt/β-catenin in various steps of hepatocarcinogenesis.

The oncogenic role of Wnt/β-catenin mutations in HCC was first investigated in transgenic mice. Importantly, transgenic mice overexpressing activated mutant forms of β-catenin develop hepatomegaly, but not HCC (54, 55). These results indicate that activation of Wnt/β-catenin alone may not be sufficient to drive hepatocarcinogenesis. Instead, a second signal is required to cooperate with activated β-catenin to induce HCC development. Consistent with this hypothesis, recent studies using hydrodynamic transfection (56) have demonstrated that oncogenic forms of β-catenin cooperate with other proto-oncogenes such as c-Met (57–59), K-Ras12v (60), activated Akt (61), LKB1 (62), and Nrf2 (63) to induce HCC formation in mice (Table 1). In human HCCs, coordinated activation of c-Met and β-catenin was found in approximately 10% of samples (64). While overexpression of c-Met or the activated mutant form of β-catenin via hydrodynamic injection alone cannot promote HCC formation in mice, coexpression of c-Met and activated β-catenin induces liver tumor development within 6–8 weeks after injection (58). Concomitant CTNNB1 mutations and NFE2L2/KEAP1 mutations, which lead to activation of the Nrf2 pathway, occur in approximately 9% of human HCCs (65). Coexpression of activated forms of β-catenin with mutant NFE2L2, but not the wild-type form of NFE2L2, can induce HCC development in mice (66). Loss-of-function AXIN1 mutations and c-Met activation were detected in approximately 4% of human HCC, and coexpression of c-Met together with CRISPR/Cas9–based targeting of Axin1 (sgAxin1) in the mouse liver triggers HCC formation (59). Consequent RNA-Seq studies have demonstrated that these murine HCCs share similar gene expression patterns to the subset of human HCCs harboring similar genetic events. In addition, TERT promoter mutations are found in many HCC tissues with CTNNB1 mutations, indicating a possible synergistic effect of these two genes (65, 66).

Once activated, β-catenin triggers the induction of downstream target expression via the TCF/LEF1 family of transcription factors. Many of these target genes are implicated in hepatocarcinogenesis. c-MYC is one of the best-characterized downstream effectors of β-catenin. However, c-MYC is also regulated by many other mechanisms, such as amplification of the c-MYC locus, increased protein stability, and activation of estrogen receptor, Ras/Raf, and IFN-γ pathways (67–69). c-MYC was first identified as a Wnt/β-catenin target gene in the human HT29 colorectal cancer cell line harboring mutant APC alleles (70). Subsequently, multiple Wnt response elements were identified in the c-MYC promoter (71). Furthermore, in human HCC, c-MYC could be induced by β-catenin activation (72, 73), and this pathway plays a critical role in gankyrin-driven increased glycolysis and glutaminolysis (74) as well as in sorafenib responsiveness (75).
Cyclin D1 is another direct target of β-catenin and might be a key molecule by which activated β-catenin promotes tumor cell proliferation (76, 77). Numerous studies have demonstrated that activated Wnt/β-catenin induces cyclin D1 expression in mouse and human HCC (78, 79). However, it is worth mentioning that cyclin D1 is not an exclusive effector of the Wnt/β-catenin signaling pathway. Indeed, other molecular cascades could regulate its expression, such as the NF-κB and MAPK pathways (80, 81). Studies conducted in vivo have also illustrated the critical role of cyclin D1 in HCC development (82). Specifically, the coexpression of c-Met and activated mutant forms of β-catenin rapidly induces HCC formation in mice; overexpression of c-Met and cyclin D1 also induces liver tumor development in mice, albeit with longer latency (58). Nevertheless, using Ccnd1-knockout mice, Patil et al. showed that cyclin D1 expression is not essential for liver tumor development induced by c-Met and activated mutant forms of β-catenin (58). Mechanistically, cyclin D2 expression in the liver is compensatorily upregulated upon cyclin D1 loss (58). Intriguingly, overexpression of cyclin D1 has also been shown to indirectly enhance the Wnt/β-catenin pathway, leading to increased HCC metastasis (83). Altogether, these studies suggest the interconnected and feedback mechanisms between cyclin D1 and Wnt/β-catenin cascades during hepatocarcinogenesis.

GS, which promotes glutamine synthesis in cells, is a liver-specific Wnt/β-catenin target (84). In normal liver, GS is expressed in a layer of pericentral hepatocytes. Liver-specific knockout of β-catenin in mice leads to complete loss of the pericentral expression of GS (85). As we discussed above, immunostaining of GS may represent a pathological marker for human HCCs with GOF CTNNB1 mutations (86), although GS expression could also be induced by other factors (87). Studies have shown that GS regulates autophagy downstream of activated β-catenin, which confers sensitivity to sorafenib. Notably, GS-mediated glutamine synthesis is required for CTNNB1-mutated HCC growth, since glutamine deprivation inhibits CTNNB1-mutated HCC growth in vitro and in vivo (88). Amino acids, including glutamine, are major regulators of mTOR activity in cells (89). Recently, it has been discovered that GS-mediated increased glutamine synthesis leads to mTORC1 activation (90). Accordingly, a strong correlation between activated β-catenin and positive expression of phosphorylated mTOR-S2448 (p-mTOR-S2448) characterizes human HCCs. In addition, CTNNB1-mutated HCCs are mTORC1-addicted, owing to the GS/glutamine/p-mTOR-S2448 axis. These studies suggest that mTORC1 inhibitors could be effective for treating CTNNB1-mutant and GS-positive human HCCs.

In addition to the genes mentioned above, activated Wnt/β-catenin drives the expression of hundreds of other genes, thus architecting a network of molecules that contributes to tumorigenesis (91, 92). For example, activated Wnt/β-catenin induces the expression of AXIN2, which functions as a negative-feedback mechanism to inhibit β-catenin, perhaps avoiding the harmful effects of a completely uncontrolled β-catenin activity (93). TBX3 is another liver-specific Wnt/β-catenin target gene that can contribute to specific pathological phenotypes via inhibition of the YAP cascade (94). Kinesin family member 2C (KIF2C) is also a direct target of the activated Wnt/β-catenin pathway (95). Its expression is upregulated in HCC and is associated with a poor prognosis. Furthermore, KIF2C enhances mTORC1 activation, providing another link between activated β-catenin and the mTOR cascade in HCC (95). In addition, Wnt/β-catenin is known to induce the expression of multiple matrix metalloproteinases (MMPs), such as MMP2 and MMP9, which contribute to tumor metastasis (96). VEGF-A and VEGF-C, key molecules promoting angiogenesis, are induced by Wnt/β-catenin (97). Moreover, Wnt/β-catenin positively regulates MCL1 expression, associated with sorafenib sensitivity in HCC (98). In addition to activating genes or pathways, Wnt/β-catenin negatively regulates signaling cascades. In the intestine, Wnt inhibits the MAPK pathway (99), whereas, in the liver, it suppresses the NF-κB cascade (100). In mice with liver-specific knockout of Ctnnb1, there is increased RelA expression and LPS-induced NF-κB activation (101). However, the inhibitory activities of the Wnt/β-catenin cascade in hepatocarcinogenesis have not been well characterized and require further investigation.

### Targeting Wnt/β-catenin for HCC treatment

Since Wnt pathway activation promotes HCC cell proliferation, migration, and invasion, targeting this signaling cascade is an attractive therapeutic approach for human HCC treatment. Several agents have been screened and investigated for targeting the

---

**Table 1. Signaling pathways that cooperate with β-catenin or Axin1 activation or mutation to drive hepatocarcinogenesis**

| Combination | Phenotype | Character | Reference |
|-------------|-----------|----------|-----------|
| c-Met and β-catenin | HCC | Malignant HCC | 57, 58 |
| c-Met and ΔN90–β-catenin | HCC | Activation of Wnt/β-catenin and Notch signaling | 59 |
| K-Ras mutant (G12D) and β-catenin mutants (S33Y, S45Y) | HCC | Increased glutamine synthetase, leukocyte cell–derived chemotaxin 2, regucalcin, and cyclin D1 and activated K-Ras effectors | 60 |
| Activated Akt and β-catenin | HCC | Steatotic hepatocellular adenomas that progressed to HCC | 61 |
| LKB1 and β-catenin | HCC | Well differentiated, almost never steatotic, and often cholestatic | 62 |
| Nrf2 and β-catenin | HCC | Positive for β-catenin targets, like glutamine synthetase and cyclin D1, and Nrf2 targets, like NAD(P)H quinone dehydrogenase 1 and peroxiredoxin 1 | 63, 153 |
| TERT and β-catenin | HCC | HCV-related HCC | 65, 66 |
| c-Met and Axin1 deletion | HCC | Activation of Wnt/β-catenin and Notch signaling | 59 |
| YAP1 and β-catenin | Hepatoblastoma | Expressed common targets of both signaling pathways | 154 |
| TAZ and β-catenin | Hepatoblastoma | Hepatoblastoma lesions exhibiting both epithelial and mesenchymal features | 155 |
Wnt pathway in cancer, and some of them are under development. Those agents include small-molecule inhibitors that block the interaction of β-catenin with TCF, such as the fungal derivatives PKF115–854 and CGP049090 (102–106), or the binding of β-catenin to cAMP response element–binding protein (CREB)-binding protein (CBP), such as ICG-001 (107–109). Both PKF115–854 and CGP049090 have shown inhibitory effects against HCC cell growth (45, 106). Therapeutic monoclonal antibodies against Wnts were also developed to block the binding of Wnts to Frizzled (FZ/FZD) receptors, such as anti-Wnt2 monoclonal antibodies (110) and the anti-FZD monoclonal antibody OMP-18R5 (111). Moreover, several approved drugs currently in clinical use have been shown to possess activity against the Wnt pathway (112, 113). These include indomethacin (114, 115), pyrvinium (116), sulindac (117), aspirin (114), celecoxib, and rofecoxib (118). Unfortunately, the antitumor potency of these repurposed drugs has not been established clinically.

In addition to Wnt/TCF inhibitors, agents targeting porcupine (PORCN) or tankyrase (TNKS) have also been developed to block Wnt/β-catenin signaling in cancer cells. PORCN is an O-acyltransferase essential for Wnt ligand secretion (119). The PORCN inhibitors, such as LGK-974 (WNT-974) and ETC-159, may inhibit tumor growth via suppression of Wnt signaling. Indeed, studies have shown that LGK-974 can enhance the radiosensitivity of HepG2 cells by modulating Nrf2 signaling (120), and it is investigated in clinical trials for treating various solid tumors (121). TNKS targets AXIN protein for degradation, whereas TNKS inhibition can stabilize AXIN, thus antagonizing Wnt signaling (122). Several TNKS inhibitors with promising therapeutic effects have been developed, including XAV939, GO07-LK, G244-LM, RK-287107, JW55, K-756, IWR-1, MSC2504877, AZ1366, JW74, and NVP-TNK656 (123–132). Preclinical studies have shown that TNKS inhibitors, such as XAV939, can potentially inhibit HCC growth in culture (133). However, PORCN and TNKS inhibitors target pathways upstream of β-catenin; therefore, they are unlikely to possess any efficacy against HCCs with GOF CTNNB1 mutations.

Interfering RNA– or antisense RNA–based therapy is another approach to inhibit the Wnt/β-catenin pathway. In particular, siRNAs targeting Wnts have been shown to suppress HCC cell growth in vitro (134–136). In a GOF Ctnnb1-mutant mouse HCC model induced by diethylnitrosamine (DEN) and phenobarbital, use of locked nucleic acid (LNA) antisense oligonucleotides against β-catenin strongly impaired HCC progression (137). In contrast, in the non–Ctnnb1-mutant HCC model, induced by DEN only, LNA-si–β-catenin demonstrated no efficacy (137). The therapeutic efficacy of LNA-si–β-catenin has been further validated in vivo in mouse HCCs induced by hydrodynamic transfection of activated forms of K-Ras and β-catenin oncogenes (60).

In summary, various strategies targeting the Wnt/β-catenin cascade have been developed in recent decades. Preclinical studies have provided evidence to support targeting this pathway against cancers, including HCCs. Nevertheless, considerable challenges remain, especially concerning the toxicity of these inhibitors, which suppress the Wnt/β-catenin pathway in normal tissues as well. Thus, the clinical development of these molecules has been somewhat limited to date.

Wnt/β-catenin as a biomarker for resistance to immunotherapy

Immunotherapy has become the first-line treatment strategy against advanced HCC (9). As we discussed above, in the IMbave150 phase III clinical trial for advanced-stage HCC patients, the combination of the anti–PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab demonstrated an objective response rate of 36% (8). Unfortunately, ICIs have limited efficacy as monotherapy against HCC. For instance, the anti–PD-1 monoclonal nivolumab failed to improve HCC patient survival versus sorafenib in the phase III CheckMate 459 trial (9). One of the primary reasons for the failure of these clinical trials is that no biomarker-based patient selection has been implemented. Therefore, it is plausible to hypothesize that some patients harbor genetic events that confer resistance to ICIs. In this regard, aberrant activation of Wnt/β-catenin has emerged as an important pathway mediating ICI resistance (138, 139). Harding et al. reported that in HCC patients treated with ICIs, activation of the Wnt/β-catenin pathway correlating with lower disease control rate and lower progression-free and overall survival rates (140). Furthermore, studies using mouse HCC models confirmed that upregulated Wnt/β-catenin signaling in HCC promotes immune evasion and confers resistance to anti–PD-1 therapy (141). Mechanistically, it was found that activated β-catenin inhibits CCL5 expression, leading to impaired dendritic cell recruitment. Likewise, activated β-catenin in melanoma cells enhances ATF3 expression and subsequently represses CCL4 expression, leading to reduced recruitment of dendritic cells and consequently T cells into the tumor tissues (142). These findings suggest that CTNNB1 mutational status could represent a novel biomarker for HCC patient exclusion for ICI treatment. Nevertheless, more studies are required to address the roles of the Wnt/β-catenin pathway in immunotherapy. For example, what is the Wnt/β-catenin mutation status in the IMbave150 phase III clinical trial? Does the mutation status correspond to insensitivity to the combination immunotherapy or eventual progression over the treatment? Studies have suggested that NASH-related HCCs are particularly resistant to immunotherapies (143). Because the status of the Wnt/β-catenin pathway in NASH-related HCCs has not been well characterized, this question should be addressed using human HCC tissues and preclinical approaches.

Challenges and future directions

Despite extensive studies on the Wnt/β-catenin cascade during hepatocarcinogenesis, our understanding of the molecular pathways deregulated by activated Wnt/β-catenin and how we can effectively target Wnt/β-catenin remains quite limited. Here, we discuss several key issues that need to be addressed to guide us for precision medicine.

GOF CTNNB1 mutations and LOF AXIN1 mutations: same or different? As we discussed above, both GOF CTNNB1 mutations and loss-of-function (LOF) AXIN1 mutations promote canonical Wnt pathway activation in HCC (59). Genetic studies have shown that these two mutations are mutually exclusive in human HCCs (Figure 1A), further supporting that they likely function via the major common pathway during hepatocarcinogenesis. Intriguingly, considerable differences have also been revealed based on recent genomic studies (Table 2). Specifically, HCCs with GOF CTNNB1 mutations...
Table 2. Distinct features of HCCs with AXIN1 or CTNNB1 mutations

| HCC features       | AXIN1 mutant class | CTNNB1 mutant class |
|--------------------|--------------------|---------------------|
| Mutation rate in HCC | ~8%                | ~27%                |
| Canonical Wnt pathway gene expression* | No                 | Yes                 |
| Molecular classification |                  |                     |
| Major group        | Proliferation group| Nonproliferation group |
| TCGA (clusters 1–3) | Cluster 1/3        | Cluster 2           |
| Boyault (G1–G6)    | G1/G2              | G5/G6               |
| Lee (clusters A/B) | Cluster A           | Cluster B           |
| Hoshida (S1–S3)    | S1/S2              | S3                  |
| Major signaling pathways | NOTCH signaling, YAP signaling | Canonical Wnt/β-catenin signaling, mTOR signaling |
| Genetic features                                           |
| Chromosomal stability | Instability        | Stability            |
| TP53 mutation, RPS6KA3 mutation | TERT promoter mutation, NFE2L2 | KEAP1 mutation, ARID2 mutation |
| Gene alteration                                             |
| Epigenetic features                                         |
| DNA hypomethylation |                     |                     |
| Promoter hypomethylation                                  |
| Clinical features                                           |
| Prognosis                                                   |
| More aggressive                                            | Less aggressive     |
| Differentiation                                             |
| Poor                                                        | Moderate to well    |
| Vascular invasion                                           |
| Frequent                                                    | Uncommon            |
| Serum α-fetoprotein                                         |
| High levels                                                 | Low levels          |
| Etiology                                                    |
| HBV                                                         | Alcohol, HCV        |
| **SLC1A2, NKD1, AXIN2, LGR5, RHBG, GLUL, SPS, TBX3, REG3A, DDAM, NOTUM, ZNRF3, RNF43, LAMA3, TRIB2, TNFRSF19, DAT, LEF1, SLC1A2, CYP2E1, LECT2, HAL, GLS2.**

*AXIN1 mutations are classified into the proliferation group (40). Additional molecular analysis revealed that AXIN1-mutant HCCs show relatively low canonical Wnt pathway activation levels but higher YAP/NOTCH induction, while CTNNB1-mutant HCCs show robust canonical Wnt pathway and mTOR signaling activation (144). These data suggest that GOF CTNNB1 and LOF AXIN1 might induce overlapping but also distinct downstream molecular events during hepatocarcinogenesis. It is tempting to hypothesize that LOF AXIN1-mutant HCCs, but not GOF CTNNB1-mutant tumors, depend on the YAP cascade for growth. If so, we need to understand how YAP becomes activated downstream of LOF AXIN1, and whether targeting YAP, such as using TNKS inhibitors, will lead to regression of HCC with LOF AXIN1 mutations.

What is the role of canonical Wnt/β-catenin signaling in HCCs with AXIN1 or CTNNB1 mutations? Based on the published data and the recent genomic studies, such as TCGA analysis, it is clear that Wnt ligands and their receptors are frequently upregulated in human HCC samples. However, one can also clearly see that high expression of canonical Wnt target genes, including GLUL (encoding GS) and TBX3, tracks strongly with GOF CTNNB1 mutations in human HCC samples (Figure 1A). Therefore, upregulation of Wnt ligands/receptors obviously does not induce strong activation of the canonical Wnt/β-catenin pathway. What is the functional role of the canonical Wnt/β-catenin cascade during HCC molecular pathogenesis in the absence of AXIN1 or CTNNB1 mutations? Most studies so far have relied on HCC cell lines (60, 113, 145). However, studies have suggested that Wnt ligands are likely to be produced by cells within the microenvironment. For example, in the normal liver, Wnts are secreted from sinusoid endothelial cells (146) or Kupffer cells during liver regeneration (147). The cellular sources of Wnt ligands in HCC remain to be defined. If they are secreted by the cells within the tumor microenvironment, it would be essential to investigate this canonical Wnt/β-catenin signaling in HCC when tumor cells are in their appropriate context, such as using murine HCC models. This question is critical to determine whether targeting of Wnt ligands, such as with PORCN inhibitors, may help to treat HCC without AXIN1 or CTNNB1 mutations.

Is mTOR inhibition effective for the treatment of HCCs with GOF CTNNB1 mutations? As we discussed above, activated β-catenin leads to mTORC1 activation, and mouse HCCs with GOF Ctnnb1 mutations are sensitive to mTOR inhibition (90). On the other hand, monotherapy of everolimus, an mTOR inhibitor, has limited efficacy against advanced HCC (148). However, no biomarker-based patient selection was conducted in this clinical trial. This issue represents a major drawback of the trial, as the mTOR pathway is modulated by multiple cascades in cancer (149), including HCC (150); in addition, HCC is a highly heterogeneous disease. One can envision that the selection of patients with GOF CTNNB1 mutations might be helpful to demonstrate the clinical efficacy of this drug. Furthermore, everolimus is a first-generation and partial mTORC1 inhibitor. The second-generation mTOR inhibitors, including mTORC1/mTORC2 inhibitors and mTOR/P38K inhibitors, might have improved efficacy against HCCs with GOF CTNNB1 mutations (151). Additional preclinical and clinical studies are required to address this critical issue.

Can gene editing to reverse CTNNB1 mutation be useful for HCC treatment? Recent progress with CRISPR/Cas9-based gene editing technology opens the door to genetic modification of tumor cells. GOF CTNNB1 mutations, especially point mutations, are attractive targets for such a gene editing approach for cancer treatment. One can imagine delivering the proper guide RNA into HCC cells and reversing the mutant form of the CTNNB1 allele into the wild-type sequence. However, small molecules directly targeting Wnt/β-catenin are frequently associated with significant gastrointestinal toxicity, as Wnt/β-catenin is necessary for intestinal stem cell renewal and proliferation. This toxicity substantially limits the clinical application of these small molecules. The gene editing approach has the advantage of not affecting the Wnt/β-catenin pathway in any other cells besides HCC cells that harbor the CTNNB1 mutations. However, we do not know whether conversion into the wild-type CTNNB1 sequence will lead to HCC regression, since wild-type β-catenin may be sufficient to support HCC progression. In addition, an efficient delivery method so that the guide RNAs can target all HCC cells should be developed.

Wnt inhibitors: monotherapy or combination therapy? As we discussed above, animal studies have demonstrated that the activation of Wnt/β-catenin alone is insufficient to promote HCC devel-
opment. Instead, a second oncogenic signal is required for liver tumor formation (Table 1). Therefore, it is conceivable that targeting Wnt/β-catenin alone, either directly or indirectly (such as with mTOR inhibitors), is not sufficient to induce tumor regression. In contrast, combination therapies that target multiple signaling cascades might be required for efficient therapeutics. This point is highlighted by a recent study in murine HCC models coexpressing c-Met and ΔN90-β-catenin proto-oncogenes. In these mice, combined treatment with cavozaatinib, which targets c-Met, and the dual mTOR inhibitor MLN0128, which targets activated β-catenin effectors, leads to tumor regression, whereas cavozaatinib or MLN0128 monotherapy does not (152). As HCC is a heterogeneous disease, it would be critical to determine the specific pathways aberrantly activated in each HCC. Then one could design effective anti-Wnt/β-catenin-based combination therapies.

In summary, in the era of precision medicine, we can readily detect HCCs harboring activated Wnt/β-catenin signaling. These HCCs have peculiar molecular and pathological features and might be treated with effective and specific targeted therapies. However, our understanding of how the Wnt/β-catenin pathway contributes to HCC molecular pathogenesis remains incomplete. Therefore, additional molecular and biochemical studies are required to investigate this vital issue to identify novel targeted therapies against HCC with aberrant Wnt/β-catenin activation.

Acknowledgments

We apologize to those investigators whose publications were not cited owing to space limitations. CX is supported by the National Science Foundation of China (grant 82073091). XC is supported by NIH grants R01CA204586, R01CA239251, and R01CA250227 as well as P30DK026743 to the UCSF Liver Center.

Address correspondence to: Xin Chen, Department of Bioengineering and Therapeutic Sciences, 513 Parnassus Avenue, University of California, San Francisco, California 94404, USA. Email: xin.chen@ucsf.edu.

1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Huang DQ, et al. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238.

3. Valery PC, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018;67(2):600–611.

4. Raoul JL, et al. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol. 2019;6(1):HEP11.

5. Cheng H, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019;9(8):1536–1545.

6. Sangro B, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88.

7. El-Khoueiry AB, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.

8. Finn RS, et al. Atezolizumab plus bevacizumab in first-line treatment of advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(5):4317–4345.

9. Perugorria MJ, et al. Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121–136.

10. Pez F, et al. Wnt signalling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59(5):1107–1117.

11. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843–850.

12. Benhamouche S, et al. Apc tumor suppressor gene is the “zonation-keeper” of mouse liver. Dev Cell. 2006;10(6):759–770.

13. Morgan SP. β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 2015;148(7):1294–1310.

14. Giles RH, et al. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653(1):1–24.

15. Liu P, et al. Oncogenic mutations in armadillo repeats 5 and 6 of β-catenin reduce binding to APC, increasing signaling and transcription of target genes. Gastroenterology. 2020;158(4):1029–1043.

16. Bugter JM, et al. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21(1):5–21.

17. Shih YL, et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107(3):579–590.

18. Leng A, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99(1):143–150.

19. Rana MA, et al. Interplay of Wnt signaling and miRNAs in HBV pathogenesis of liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2015;12(7):378–389.

20. Huang H, et al. Beta-catenin mutations are associated with hepatitis C virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2001;94(4):468–474.

21. Cieply B, et al. Unique phenotype of hepatocellular carcinoma. Hepat Oncol. 2013;59(1):81–88.

22. Cieply B, et al. Unique phenotype of hepatocellular carcinoma. Hepat Oncol. 2013;59(1):81–88.

23. Huang H, et al. Beta-catenin mutations are associated with hepatitis C virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2001;94(4):468–474.

24. Wang Z, et al. β-Catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol. 2015;3(4):936–940.

25. Ding X, et al. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One. 2014;9(5):e95307.

26. Lu LG, et al. β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma. Oncology. 2014;87(3):159–166.

27. Wong CM, et al. β-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92(1):136–145.

28. Mao TL, et al. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol. 2001;193(3):95–101.

29. Nhieu JT, et al. Beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol. 2001;193(3):95–101.

30. Nihieu JT, et al. Nuclear accumulation of mutant beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155(3):703–710.

31. Calderon J, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–738.

32. Lee JS, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic
mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001;61(6):3245-3249.
55. Harada N, et al. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 2004;64(1):48–54.
56. Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014;184(4):912–923.
57. Tao J, et al. Modeling a human hepatocellular carcinoma subset in mice through co-expression of met and point-mutant beta-catenin. Hepatology. 2016;64(5):1587–1605.
58. Patil MA, et al. Role of cyclin D1 as a mediator of c-Met and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 2009;69(6):253–261.
59. Qiao Y, et al. Axis inhibition protein 1 (Axin1) deletion-induced hepatocarcinogenesis requires intact beta-catenin but not notch cascade in mice. Hepatology. 2019;70(6):2003–2017.
60. Tao J, et al. Targeting beta-catenin in hepatocellular cancers induced by co-expression of mutant beta-catenin and K-Ras in mice. Hepatology. 2017;65(5):1581–1599.
61. Stauffer JK, et al. Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res. 2011;71(7):2718-2727.
62. Charawi S, et al. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates beta-catenin-dependent CTNNB1-mutated HCC. J Pathol. 2019;247(4):435–443.
63. Tao J, et al. Nuclear factor erythroid 2-related factor 2 and beta-catenin coactivation in hepatocellular carcinoma: biological and therapeutic implications. Hepatology. 2021;74(2):741–750.
64. Zhan N, et al. The effect of selective c-MET inhibitor on hepatocellular carcinoma in the MET-active, beta-catenin-mutated mouse model. Gene Express. 2018(12):135–147.
65. Pezzuto F, et al. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget. 2016;7(34):54253–54262.
66. Lee SE, et al. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma. Oncotarget. 2016;7(43):69267–69275.
67. Dubik D, Shiui RP. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem. 1988;263(25):12705–12708.
68. Kerkhoff E, et al. Regulation of c-myc expression by Ras/Raf signalling. Oncogene. 1998;16(2):211–216.
69. Ramana CV, et al. Regulation of c-myc expression by IGF-signalling through Stat1-dependent and -independent pathways. EMBO J. 2000;19(2):263–272.
70. He TC, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–1512.
71. Remmelm S, Yochum G. Regulation of MYC gene expression by aberrant Wnt/beta-catenin signaling in colorectal cancer. World J Bio Chem. 2015(6):290–300.
72. Shang ZX, et al. Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. Lab Invest. 2004;84(3):332-341.
73. Tong Z, et al. Steroid receptor coactivator 1 promotes human hepatocellular carcinoma progression by enhancing Wnt/beta-catenin signaling. J Biol Chem. 2015;290(30):18596-18608.
74. Liu R, et al. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating beta-catenin/C-Myc signaling in human hepatocellular carcinoma. Cancer Lett. 2019;443:34–46.
75. Qiao Y, et al. Oncogenic potential of N-terminal deletion and 545Y mutant beta-catenin in promoting hepatocellular carcinoma development in mice. BMC Cancer. 2018;18(1):1093.
76. Shuttman M, et al. The cyclin D1 gene is a target of the beta-catenin/LEF1 pathway. Proc Natl Acad Sci U S A. 1999;96(10):5522–5527.
77. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422–426.
78. Delgado E, et al. Beta-Catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid. Curr Cancer Drug Targets. 2013;13(8):867–878.
79. Kaur P, et al. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol. 2012;33(2):325–336.
80. Guttridge DC, et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19(8):5783–5799.
81. Klein EA, Assion RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci. 2008;121(pt 23):3853–3857.
82. Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016;94(12):1313-1326.
83. Tang B, et al. Overexpression of CTNNDI in hepatocellular carcinoma promotes carcinogenic characters through activation of Wnt/beta-catenin signaling. J Exp Clin Cancer Res. 2016;35(1):82.
84. Cadoret A, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002;21(54):8293–8301.
85. Sekine S, et al. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology. 2006;43(4):817–825.
86. Lee JM, et al. Beta-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett. 2014;343(1):90–97.
87. Austimat M, et al. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer. 2008;7:21.
88. Chiu M, et al. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer. 2014;111(6):1159–1167.
89. Krall AS, et al. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun. 2016;7:11437.
90. Adebayo Michael AO, et al. Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by beta-catenin mutations. Cell Metab. 2019;29(5):1135–1150.
91. Clevers H, Nusse R. Wnt/beta-catenin signaling and...
The Journal of Clinical Investigation

92. Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999.

93. Lustig B, et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axonin2 in colorectal and liver tumors. Mol Cell Biol. 2002;22(4):1184–1193.

94. Liang B, et al. TBX3 functions as a tumor suppressor in colorectal cancer cells. Cancer Lett. 2014;352(2):394–403.

95. Wei S, et al. KIF2C: a novel link between Wnt/beta-catenin signaling and colorectal cancer progression. Oncotarget. 2015;6(23):20410–20420.

96. Wang C, et al. Silencing of KIF3B suppresses breast cancer progression by regulating EMT and Wnt/beta-catenin signaling. Front Oncol. 2020;10:597464.

97. Qu B, et al. Wnt/beta-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. Oncol Lett. 2014;7(4):1175–1178.

98. Lin HH, et al. Inhibition of the Wnt/beta-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Lett. 2016;381(1):58–66.

99. Kabiri Z, et al. Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. J Clin Invest. 2018;128(9):3806–3812.

100. Ma B, Hottiger MO. Cross-talk between Wnt/beta-catenin and NF-κB signaling pathway during inflammation. Front Immunol. 2016;7:378.

101. Nejak-Bowen K, et al. Beta-catenin-NF-κB interactions in murine hepatocytes: a complex to die for. Hepatology. 2013;57(2):763–774.

102. Lepourcellet M, et al. Small-molecule antagonists of the oncopgenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5(1):91–102.

103. Sukhdeo K, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007;104(8):7516–7521.

104. Minke KS, et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol. 2009;82(3):165–175.

105. Gandhirajan RK, et al. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in colorectal cancer cells. Br J Cancer. 2014;110(1):224–229.

106. Wang XH, et al. Targeting Wnt/beta-catenin signaling through upregulation of conductin/beta-catenin. Int J Cancer. 2012;72(11):2822–2832.

107. Okada-Iwasaki R, et al. The discovery and characterization of K-756, a novel Wnt/beta-catenin pathway inhibitor targeting tankyrase. Mol Cancer Ther. 2016;15(7):1525–1534.

108. Busch AM, et al. Evidence for tankyrases as anti-neoplastic targets in lung cancer. BMC Cancer. 2013;13:211.

109. Menon M, et al. A novel tankyrase inhibitor, MSCP204877, enhances the effects of clinical CDK4/6 inhibitors. Sci Rep. 2019;9(1):201.

110. Quackenbush KS, et al. The novel tankyrase inhibitor (AZ1566) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget. 2016;7(19):28273–28285.

111. Strandfor EW, et al. The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med. 2014;3(1):36–46.

112. Arques O, et al. Tankyrase inhibition blocks Wnt/beta-catenin pathway and reverses resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2016;22(3):644–656.

113. Wang XH, et al. Beta-catenin siRNA regulation of beta-catenin accumulation and Wnt signaling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90(1):224–229.

114. Yamada T, Takada R, et al. Indomethacin induces differentiation of Wnt protein: its role in Wnt secretion. Cancer Res. 2014;74(3):706–715.

115. Wang XH, et al. Targeting Wnt/beta-catenin signaling through upregulation of conductin/beta-catenin. Front Oncol. 2012;2:58–66.

116. Wang XH, et al. Targeting Wnt/beta-catenin signaling through upregulation of conductin/beta-catenin. Front Oncol. 2012;2:1525–1534.

117. Wang XH, et al. Targeting Wnt/beta-catenin signaling through upregulation of conductin/beta-catenin. Front Oncol. 2012;2:58–66.

118. Wang XH, et al. Targeting Wnt/beta-catenin signaling through upregulation of conductin/beta-catenin. Oncotarget. 2015;6(28):25390–25401.

119. Sangkhathat S, et al. In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hematologic tumors. Int J Oncol. 2006;28(3):715–722.

120. Tang JI, et al. Potential of small molecule inhibitors of Wnt/beta-catenin signaling as therapeutic agents for hematologic malignancies. Expert Opin Investig Drugs. 2013;22(1):1–13.

121. Yang XG, et al. Current advance of therapeutic agents in clinical trials potentially targeting the beta-catenin pathway as a molecular target for colorectal tumor growth. J Hematol Oncol. 2017;10(1):101.

122. Chehrazi-Raffle A, et al. Wnt/beta-catenin signaling and immunotherapy resistance: lessons for the treatment of uterine cervical carcinoma. Cancers (Basel). 2021;13(4):889.

123. Harding JL, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25(7):2116–2126.

124. Ruiz de Galarreta M, et al. Wnt/beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–1141.

125. Spranger S, et al. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–235.

126. Pfister D, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–456.

127. Abitbol S, et al. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation. J Hepatol. 2018;68(6):1203–1213.
145. Ding Z, et al. Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation. Oncotarget. 2017;8(70):114526–114539.
146. Zeng G, et al. Wnt’er in liver: expression of Wnt and frizzled genes in mouse. Hepatology. 2007;45(1):195–204.
147. Yang J, et al. β-catenin signaling in murine liver zonation and regeneration: a Wnt-Wnt situation! Hepatology. 2014;60(3):964–976.
148. Zhu AX, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57–67.
149. Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183–203.
150. Matter MS, et al. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60(4):855–865.
151. Lu X, et al. Role of the mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies. Hepatology. 2021;73(suppl 1):49–61.
152. Shang R, et al. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut. 2021;70(9):1746–1757.
153. Savall M, et al. Cooperation between the NRF2 pathway and oncogenic β-catenin during HCC tumorigenesis. Hepatol Commun. 2021;5(9):1490–1506.
154. Tao J, et al. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147(3):690–701.
155. Zhang S, et al. The hippo effector transcriptional coactivator with PDZ-binding motif cooperates with oncogenic β-catenin to induce hepatoblastoma development in mice and humans. Am J Pathol. 2020;190(7):1397–1413.